A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Part of paid clinical trials in Columbus, Ohio.

Sponsor
UCB Biopharma SRL
Study ID
NCT07219420
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Palmoplantar Pustulosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Study participants will receive bimekizumab at pre-specified time points.
  • Placebo — DRUG
    Study participants will receive matching placebo at pre-specified time points.

Study Details

The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).

Key Dates

Start date
Nov 14, 2025
Status verified
Jun 2026
Primary completion
Dec 27, 2027
Completion
Nov 22, 2029

Study Design

Enrollment
320 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab
    Subjects randomized to this arm will receive the bimekizumab dosing regimen for the entire duration of the study.
  • Placebo Comparator: Placebo
    Subjects randomized to this arm will receive placebo during the initial treatment period before transitioning to bimekizumab in the maintenance treatment period.

Primary Outcome Measure

Palmoplantar pustulosis-Investigator Global Assessment 0/1 (PPP-IGA 0/1) response at Week 16 [ Time Frame: At Week 16 ]

Central Contacts

Locations (1)

FacilityCityStateZIP
Ppp001 50745ColumbusOhio43213

Find similar trials in Columbus, OH

By research site
Ppp001 50745· Columbus, OH

Related Studies